文献速递甲状腺疾病

甲状腺激素类似物:近期进展

Thyroid Hormone Analogs: Recent Developments.
PubMed 文献 · Thyroid · 2025-07-14

本综述更新2020年以来甲状腺激素类似物的进展。MGL-3196(resmetirom)改善肝脂肪变性、纤维化和血脂,2024年获美国食品药品监督管理局批准治疗MASH;Triac获欧洲药品管理局上市许可,成为首个获批治疗MCT8缺乏症的药物。

要点

  • resmetirom改善肝脂肪变性、纤维化和血脂,2024年获FDA批准治疗MASH。
  • Triac获EMA上市许可,成为首个获批治疗MCT8缺乏症的药物。
  • VK2809通过肝脏前药转化实现器官特异性,结果待报告。

核心结论

  • 提高甲状腺激素类似物器官特异性的策略应包括TR特异性及组织特异性转运体或前药激活酶等决定因素,结合近期两种类似物获批,该领域发展前景可期。

研究设计与样本

  • 综述,检索2020年以来甲状腺激素类似物领域的发展。

主要发现

  • MGL-3196(resmetirom)临床试验显示肝脂肪变性、纤维化和血脂显著改善,2024年获美国食品药品监督管理局批准治疗MASH。
  • 前药VK2809通过肝脏前药转化实现器官特异性,靶向MASH,结果目前待报告。
  • Triac以同情用药方式用于RTHβ;在MCT8缺乏症中已探索3,5-diiodothyropropionic acid,Sob-AM2(活性化合物在脑内蓄积的前药)已在临床前研究中考察。
  • 欧洲药品管理局已授予Triac上市许可,成为首个获批治疗MCT8缺乏症这一罕见病的药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid hormone exerts its function on virtually all tissues in the human body through binding to the thyroid hormone receptor (TR), making it an interesting vehicle for therapeutic intervention in nonthyroid conditions with metabolic consequences, as well as genetic thyroid hormone signaling disorders. Since the 1990s, several thyroid hormone analogs have been developed that have tissue specificity. Given the recent approval of two thyroid hormone analogs, the aim of this review is to give an update on developments in the field since 2020. Summary: Although initial therapeutic use of thyroid hormone analogs for nonthyroid conditions with metabolic consequences focused on cardiovascular disease and dyslipidemia, nowadays the primary focus is on the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Clinical trials with MGL-3196 (resmetirom) showed significant improvement on hepatic steatosis, fibrosis, and lipids, which led to approval by the U.S. Food and Drug Administration in 2024 for the treatment of MASH. Results are currently awaited for prodrug VK2809, exerting organ specificity through prodrug conversion in the liver, ultimately targeting MASH. For the treatment of genetic thyroid hormone signaling disorders (resistance to thyroid hormone β [RTHβ] and monocarboxylate transporter 8 [MCT8] deficiency), different thyroid hormone analogs have been tested. 3,5,3'-triiodothyroacetic acid (Triac), an endogenous thyroid hormone analog, has been prescribed on a compassionate use basis for RTHβ. In MCT8 deficiency, 3,5-diiodothyropropionic acid has been explored in patients, and Sob-AM2, a prodrug of which the active compound accumulates in the brain, has been investigated in preclinical studies. Recently, the European Medicines Agency has granted market authorization for Triac, being the first approved medicine for this rare disease. Conclusions: Ongoing strategies to enhance organ specificity of thyroid hormone analogs should include not only TR specificity but also other determinants of tissue selectivity, such as tissue-specific transporters or enzymes that activate the prodrug. This, together with the recent approval of two thyroid hormone analogs, may ensure a promising future for the development and application of thyroid hormone analogs.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Freund MET, van der Most F, Groeneweg S, et al. Thyroid Hormone Analogs: Recent Developments. Thyroid. 2025. PMID: 40658132. doi:10.1089/thy.2025.0245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。